Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio

Liver Transplantation

Volumn 21, Issue 5, 2015, Pages 690-695

  Rogier, Julien ^a   Roullet, Stéphanie ^a   Cornélis, François ^a   Biais, Matthieu ^a   Quinart, Alice ^a   Revel, Philippe ^a   Bioulac Sage, Paulette ^a   Le Bail, Brigitte ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATTENUATION; BIOPSY NEEDLE; BRAIN DEATH; CADAVER DONOR; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EVENT FREE SURVIVAL; FATTY LIVER; FEMALE; GOLD STANDARD; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LENGTH OF STAY; LIVER BIOPSY; LIVER HISTOLOGY; LIVER TO SPLEEN ATTENUATION RATIO; LIVER TRANSPLANTATION; MACROVESICULAR LIVER STEATOSIS; MALE; MIDDLE AGED; NON INVASIVE PROCEDURE; ORGAN TRANSPLANTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; AGED; BIOPSY; CADAVER; DONOR; DOUBLE BLIND PROCEDURE; LIVER; PROCEDURES; PROSPECTIVE STUDY; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; RISK; SPLEEN;

ADULT; AGED; BIOPSY; BRAIN DEATH; CADAVER; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPLEEN; TISSUE DONORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928547474     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24105     Document Type: Article

References (36)

1. Renz JF, Kin C, Kinkhabwala M, Jan D, Varadarajan R, Goldstein M, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg 2005; 242: 556-563.
2. Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, et al. The biopsied donor liver: Incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010; 16: 874-884.
3. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al.; for All contributing centers (www.eltr.org); European Liver and Intestine Transplant Association (ELITA). Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688.
4. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993; 55: 807-813.
5. Karatzas T, Olson L, Ciancio G, Burke GW, 3rd, Spires G, Cravero L, et al. Expanded liver donor age over 60 years for hepatic transplantation. Transplant Proc 1997; 29: 2830-2831.
6. Dutkowski P, Schlegel A, Slankamenac K, Oberkofler CE, Adam R, Burroughs AK, et al. The use of fatty liver grafts in modern allocation systems: Risk assessment by the balance of risk (BAR) score. Ann Surg 2012; 256: 861-869.
7. Biesterfeld S, Knapp J, Bittinger F, Götte H, Schramm M, Otto G,. Frozen section diagnosis in donor liver biopsies: observer variation of semiquantitative and quantitative steatosis assessment. Virchows Arch 2012; 461: 177-183.
8. Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW Jr,. Frozen section evaluation of donor livers before transplantation. Transplantation 1993; 56: 1403-1409.
9. Imber CJ, St Peter SD, Handa A, Friend PJ,. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002; 8: 415-423.
10. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500-505.
11. Urena MA, Moreno Gonzalez E, Romero CJ, Ruiz-Delgado FC, Moreno Sanz C,. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenterology 1999; 46: 1164-1173.
12. Selzner M, Clavien PA,. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-113.
13. Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, et al. Effect of macrovesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transpl 2001; 15: 53-57.
14. McCormack L, Clavien PA,. Understanding the meaning of fat in the liver. Liver Transpl 2005; 11: 137-139.
15. Deroose JP, Kazemier G, Zondervan P, Ijzermans JN, Metselaar HJ, Alwayn IP,. Hepatic steatosis is not always a contraindication for cadaveric liver transplantation. HPB (Oxford) 2011; 13: 417-425.
16. Canelo R, Braun F, Sattler B, Klinge B, Lorf T, Ramadori G, Ringe B,. Is a fatty liver dangerous for transplantation? Transplant Proc 1999; 31: 414-415.
17. Sirlin CB,. Noninvasive imaging biomarkers for steatosis assessment. Liver Transpl 2009; 15: 1389-1391.
18. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-112.
19. Castera L,. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab 2008; 34 (pt 2): 674-679.
20. Del Poggio P, Colombo S,. Is transient elastography a useful tool for screening liver disease? World J Gastroenterol 2009; 15: 1409-1414.
21. Liu ZJ, Gong JP, Yan LN,. Quantitative estimation of the degree of hepatic macrovesicular steatosis in a disease-free population: a single-center experience in mainland China. Liver Transpl 2009; 15: 1605-1612.
22. Adani GL, Baccarani U, Sainz-Barriga M, Lorenzin D, Bresadola V, Risaliti A, et al. The role of hepatic biopsy to detect macrovacuolar steatosis during liver procurement. Transplant Proc 2006; 38: 1404-1406.
23. Bohte AE, van Werven JR, Bipat S, Stoker J,. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011; 21: 87-97.
24. Bravo AA, Sheth SG, Chopra S,. Liver biopsy. N Engl J Med 2001; 344: 495-500.
25. Lo IJ, Lefkowitch JH, Feirt N, Alkofer B, Kin C, Samstein B, et al. Utility of liver allograft biopsy obtained at procurement. Liver Transpl 2008; 14: 639-646.
26. Gawrieh S, Knoedler DM, Saeian K, Wallace JR, Komorowski RA,. Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Pathol 2011; 15: 19-24.
27. Burt AD,. Steatosis and steatohepatitis. Curr Diagn Pathol 2001; 7: 141-147.
28. Burt AD, Mutton A, Day CP,. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15: 246-258.
29. Brunt EM, Tiniakos DG,. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-5296.
30. Dutkowski P, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, Müllhaupt B, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the Model for End-Stage Liver Disease era. Ann Surg 2011; 254: 745-754.
31. Frankel WL, Tranovich JG, Salter L, Bumgardner G, Baker P,. The optimal number of donor biopsy sites to evaluate liver histology for transplantation. Liver Transpl 2002; 8: 1044-1050.
32. Nousbaum JB, Cadranel JF, Bonnemaison G, Bourlière M, Chiche L, Chor H, et al. Clinical practice guidelines on the use of liver biopsy [in French]. Gastroenterol Clin Biol 2002; 26: 848-878.
33. Boulard G, Guiot P, Pottecher T, Tenaillon A,. Prise en charge des sujets en état de mort encéphalique dans l'optique d'un prélèvement d'organes. Conférence d'experts SFAR/SRLF/Agence de la Biomédecine. http://www.sfmu.org/documents/consensus/ce-pec-etatmortenceph-po.pdf. Published 2005. Agence de la Biomédecine; saint-Denis La Plaine, France. Accessed March 23, 2015.
34. Nakagawa TA, Ashwal S, Mathur M, Mysore M.,; for Society of Critical Care Medicine, Section on Critical Care and Section on Neurology of American Academy of Pediatrics; Child Neurology Society. Clinical report-guidelines for the determination of brain death in infants and children: an update of the 1987 task force recommendations. Pediatrics 2011; 128: e720-740.
35. Shemie SD, Hornby L, Baker A, Teitelbaum J, Torrance S, Young K, et al.; for The International Guidelines for Determination of Death phase 1 participants, in collaboration with the World Health Organization. International guideline development for the determination of death. Intensive Care Med 2014; 40: 788-797.
36. Société Française de Neuroradiologie, Société Française de Radiologie, Agence de la Biomédecine. Recommendations on diagnostic criteria of brain death by the technique of CT angiography [in French]. J Neuroradiol 2011; 38: 36-39.